- Home
- BIIB vs WRB Comparison
BIIB vs WRB Comparison
Compare BIIB & WRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- WRB
- Stock Information
- Founded
- BIIB 1978
- WRB 1967
- Country
- BIIB United States
- WRB United States
- Employees
- BIIB N/A
- WRB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- WRB Property-Casualty Insurers
- Sector
- BIIB Health Care
- WRB Finance
- Exchange
- BIIB Nasdaq
- WRB Nasdaq
- Market Cap
- BIIB 25.1B
- WRB 22.3B
- IPO Year
- BIIB 1991
- WRB N/A
- Fundamental
- Price
- BIIB $149.02
- WRB $58.71
- Analyst Decision
- BIIB Buy
- WRB Buy
- Analyst Count
- BIIB 26
- WRB 13
- Target Price
- BIIB $248.00
- WRB $66.92
- AVG Volume (30 Days)
- BIIB 1.6M
- WRB 1.4M
- Earning Date
- BIIB 02-11-2025
- WRB 01-22-2025
- Dividend Yield
- BIIB N/A
- WRB 0.99%
- EPS Growth
- BIIB 10.05
- WRB 17.95
- EPS
- BIIB 11.06
- WRB 3.90
- Revenue
- BIIB $9,607,500,000.00
- WRB $13,192,566,000.00
- Revenue This Year
- BIIB N/A
- WRB N/A
- Revenue Next Year
- BIIB N/A
- WRB $9.66
- P/E Ratio
- BIIB $13.47
- WRB $15.06
- Revenue Growth
- BIIB N/A
- WRB 10.53
- 52 Week Low
- BIIB $145.07
- WRB $46.48
- 52 Week High
- BIIB $268.30
- WRB $65.49
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- WRB 38.70
- Support Level
- BIIB $145.07
- WRB $56.88
- Resistance Level
- BIIB $149.92
- WRB $59.15
- Average True Range (ATR)
- BIIB 3.81
- WRB 1.06
- MACD
- BIIB 0.05
- WRB -0.47
- Stochastic Oscillator
- BIIB 22.51
- WRB 24.73
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.